Search

Displaying results 3261 - 3270 of 4575 in total
  1. Drug

    Lometrexol

    go.drugbank.com/drugs/DB12769
    Investigational

    Lometrexol has been used in trials studying the treatment of Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, and Unspecified Adult Solid Tumor, Protocol Specific.

  2. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    It is being developed by Osteologix Inc.

  3. Drug

    Psilocybin

    go.drugbank.com/drugs/DB11664
    Investigational

    In November, 2019, it was granted Breakthrough Therapy status by the FDA.

  4. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  5. Drug

    mRNA-3351

    go.drugbank.com/drugs/DB17718
    Experimental

    Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome

  6. Drug

    Clofedanol

    go.drugbank.com/drugs/DB04837
    ApprovedWithdrawn

    Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.

  7. Drug

    Anisindione

    go.drugbank.com/drugs/DB01125
    Approved

    Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the form...

  8. Drug

    Doxapram

    go.drugbank.com/drugs/DB00561
    ApprovedInvestigationalVet approved

    A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)

  9. Drug

    Pentazocine

    go.drugbank.com/drugs/DB00652
    ApprovedVet approved

    The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)

  10. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    It is subsequently isolated by homogenization of cells and purification by several chromatography steps, including hydrophobic interaction and ion exchange chromatography [FDA Label]. … When activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.